Eyeworld

EW ASCRS•ASOA 2017 72 ASCRS•ASOA Program Preview • May 5–9, 2017 finally give us the potential to make glaucoma more of a surgical disease. Eye drops will always be an import- ant part of glaucoma therapy, but it will be good for patients if surgery plays a much bigger role than it does now," he said. Just as it was decades before Dr. Kelman's invention of phacoemulsi- fication became mainstream for cat- aract surgery, so too, Dr. Brown said, and also the more philosophical resistance to change when a new option faces already established treatment paradigms. While the existing paradigm for glaucoma treatment starts with medical therapies (eye drops), Dr. Brown said he's always felt it should be a surgically treated disease. "Medical therapy is very expen- sive, causes many side effects, and compliance is terrible. We know that many patients continue to lose vision despite seeming to have good control with drops. Surgery elimi- nates most of these problems but only if it is safe and effective. The development of MIGS and the new surgical technology gives us a better combination of 'safe and effec- tive' than we have ever had. These breakthrough surgical treatments efforts for surgical glaucoma therapy have only in the last 5 years started making their way to patients. "When surgeons today use phaco—or when they implant an iStent—it may look like an obvious innovation that was inevitable and quickly adopted. The truth is that it took decades of development, many millions of dollars, and overcoming so much resistance for these innova- tions to look like 'overnight success- es,'" he said. Dr. Brown has authored more than 90 peer-reviewed articles on glaucoma and cataract surgery. He served as chairman of the ASCRS Glaucoma Clinical Committee from 2006 to 2010 and is currently the editor of the Glaucoma section in EyeWorld magazine. In addition to this honor, Dr. Brown received the Innovator Award from the Ameri- can Glaucoma Society in 2014, the Senior Achievement Award from the American Academy of Ophthalmol- ogy in 2009, and the Distinguished Alumnus Award from the Wilmer Institute in 2013. Dr. Brown deliv- ered the Obstbaum Lecture at the 2011 ASCRS Glaucoma Day. "Next time you are in the operating room, look around at all of the equipment. Each item was invented or developed by a person or group who wanted to solve a problem or make some process bet- ter. It is likely that you are as smart as they are/were. The difference is that they tried to change some- thing or improve it. We all do many things every day in the OR that we know could be better. My advice is to think about what it would take to make it better. Break down the process and focus on the difficult or problem steps. Why do we always do it this way and yet it always leads to the same problem? How would you like to change it? What would it take? Then, do it! We only know what has been invented—we don't know what hasn't," Dr. Brown said. The 2017 Charles D. Kelman, MD, Innovator's Lecture will take place Monday, May 8, as part of the ASCRS Innovators General Session from 10:00–11:30 a.m. EW Editors' note: Dr. Brown has financial interests with Glaukos, Allergan, Rhein Medical (St. Petersburg, Florida), Alcon (Fort Worth, Texas), and Aerie Pharma- ceuticals (Irvine, California). Contact information Brown: reaymary@comcast.net April 2017 ©2017 Clarity Medical Systems Inc. PN 99-100396 Rev A 12/16 Only HOLOS IntraOp ™ Wavefront Aberrometer delivers Continuous Real-time ™ actionable data to help you confirm target refractions, deliver precise astigmatic correction, and predict IOL power using the exclusive HOLOS Barrett IOL Formula ™ . HOLOS is available now. HOLOS.com holos @ claritymsi.com Accurate IOL prediction, coming at you in real time. The New Standard in Wavefront Aberrometry • Accurate intraoperative IOL prediction with the exclusive HOLOS Barrett IOL Formula ™ • Continuous Real-time ™ feedback at 90 refractions per second • Precise guidance during toric IOL rotation for enhanced astigmatic correction Visit Us at ASCRS 2017 in Booth 1147 Reay H. Brown, MD continued from page 70

• Blank Page
• Blank Page (1)